199 related articles for article (PubMed ID: 31277831)
1. How Prevalent Are Implausible EQ-5D-5L Health States and How Do They Affect Valuation? A Study Combining Quantitative and Qualitative Evidence.
Yang Z; Feng Z; Busschbach J; Stolk E; Luo N
Value Health; 2019 Jul; 22(7):829-836. PubMed ID: 31277831
[TBL] [Abstract][Full Text] [Related]
2. Implausible States: Prevalence of EQ-5D-5L States in the General Population and Its Effect on Health State Valuation.
Marten O; Mulhern B; Bansback N; Tsuchiya A
Med Decis Making; 2020 Aug; 40(6):735-745. PubMed ID: 32696728
[TBL] [Abstract][Full Text] [Related]
3. Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.
Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
Value Health; 2019 Jan; 22(1):38-44. PubMed ID: 30661632
[TBL] [Abstract][Full Text] [Related]
4. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
5. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
McClure NS; Sayah FA; Xie F; Luo N; Johnson JA
Value Health; 2017 Apr; 20(4):644-650. PubMed ID: 28408007
[TBL] [Abstract][Full Text] [Related]
6. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
[TBL] [Abstract][Full Text] [Related]
7. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
8. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
[TBL] [Abstract][Full Text] [Related]
9. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
10. Estimating an EQ-5D-5L Value Set for China.
Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K
Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009
[TBL] [Abstract][Full Text] [Related]
11. EQ-5D-5L norms for the urban Chinese population in China.
Yang Z; Busschbach J; Liu G; Luo N
Health Qual Life Outcomes; 2018 Nov; 16(1):210. PubMed ID: 30409137
[TBL] [Abstract][Full Text] [Related]
12. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
[TBL] [Abstract][Full Text] [Related]
13. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
14. Toward a Smaller Design for EQ-5D-5L Valuation Studies.
Yang Z; Luo N; Oppe M; Bonsel G; Busschbach J; Stolk E
Value Health; 2019 Nov; 22(11):1295-1302. PubMed ID: 31708067
[TBL] [Abstract][Full Text] [Related]
15. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
Karim S; Craig BM; Groothuis-Oudshoorn CGM
Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
[TBL] [Abstract][Full Text] [Related]
16. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
[TBL] [Abstract][Full Text] [Related]
17. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
Gandhi M; Rand K; Luo N
Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
[TBL] [Abstract][Full Text] [Related]
20. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?
Luo N; Cheung YB; Ng R; Lee CF
Health Qual Life Outcomes; 2015 Oct; 13():166. PubMed ID: 26438167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]